Back to News
Market Impact: 0.35
First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug
Source: Nasdaq
Healthcare & BiotechProduct Launches
Telix Pharmaceuticals dosed the first U.S. patient with Pixclara (floretyrosine F 18, or 18F-FET), marking the commercial launch of its FDA-approved imaging agent for glioma. The announcement signals the start of U.S. commercialization, but provides no sales or uptake figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
TLX0.75
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Meta may ditch the idea of a cloud business for Muse. We think that’s a good trade
- Mistral unveils new AI model it says rivals best open systems from China
- Muse has been a boon for Meta. It can soar much higher, Wells Fargo says
- Why is Natera stock sliding today?
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD